Patents by Inventor Jack A. Roth

Jack A. Roth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6143290
    Abstract: Described are simplified and efficient methods for preparing recombinant adenovirus using liposome-mediated cotransfection and the direct observation of a cytopathic effect (CPE) in the transfected cells. Also disclosed are compositions and methods involving novel p53 adenovirus constructs, including methods for restoring p53 function and tumor suppression in cells and animals having abnormal p53.
    Type: Grant
    Filed: April 7, 1994
    Date of Patent: November 7, 2000
    Assignee: The Board of Regents, University of Texas System
    Inventors: Wei-Wei Zhang, Jack A Roth
  • Patent number: 6133416
    Abstract: The present invention involves the identification of a factor or factors that are anti-proliferative and can be used in the treatment of cancers and other hyperproliferative disease states. The factor or factors are induced from cells follow contact of the cells with viral or plasmid expression vectors. One factor is between about 3 kDa and 300 kDa in size, while another is less than about 3 kDa in size. Both are heat stable and is resistant to both protease and nuclease treatment. Methods for purification and use of the factor also are disclosed.
    Type: Grant
    Filed: August 22, 1997
    Date of Patent: October 17, 2000
    Assignee: The University of Texas System Board of Regents
    Inventors: Deborah R. Wilson, Mary Lapadat-Tapolsky, Therese M. Timmons, Julia A. Lee, Brian D. Almond, Jack A. Roth
  • Patent number: 6110744
    Abstract: The present invention provides viral vectors that have been engineered to contain a synthetic promoter that controls at least one essential gene. The synthetic promoter is induced by a specific gene product not normally produced in the cells in which the viral vector is to be transferred. The vectors are propagated in producer or helper cells that express the inducing factor, thereby permitting the virus to replicate to high titer. The lack of the inducing factor in the target cells precludes viral replication, however, meaning that no vector toxicity or immunogenicity arises. Where the virus carries a gene of interest, this should provide for higher level expression for longer periods of time than with current vectors. Methods for making the vectors, helper cells, and their use in protein production, vaccines and gene therapy are disclosed.
    Type: Grant
    Filed: November 12, 1997
    Date of Patent: August 29, 2000
    Assignee: Board of Regents, The University of Texas System
    Inventors: Bingliang Fang, Jack A. Roth
  • Patent number: 6069134
    Abstract: The present invention relates to the use of tumor suppressor genes in combination with a DNA damaging agent or factor for use in killing cells, and in particular cancerous cells. A tumor suppressor gene, p53, was delivered via a recombinant adenovirus-mediated gene transfer both in vitro and in vivo, in combination with a chemotherapeutic agent. Treated cells underwent apoptosis with specific DNA fragmentation. Direct injection of the p53-adenovirus construct into tumors subcutaneously, followed by intraperitoneal administration of a DNA damaging agent, cisplatin, induced massive apoptotic destruction of the tumors. The invention also provides for the clinical application of a regimen combining gene replacement using replication-deficient wild-type p53 adenovirus and DNA-damaging drugs for treatment of human cancer.
    Type: Grant
    Filed: October 17, 1997
    Date of Patent: May 30, 2000
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jack A. Roth, Toshiyoshi Fujiwara, Elizabeth A. Grimm, Tapas Mukhopadhyay, Wei-Wei Zhang, Laurie B. Owen-Schaub
  • Patent number: 6017524
    Abstract: Disclosed are methods and compositions for the selective manipulation of gene expression through the preparation of retroviral expression vectors for expressing antisense sequences, such as K-ras oncogene antisense sequences, or sequences encoding a desired product, such as wild type p53 sequences. Preferred retroviral vectors of the present invention incorporate the .beta.-actin promoter in a reverse orientation with respect to retroviral transcription. Preferred antisense RNA constructs of the present invention employ the use of antisense intron DNA corresponding to distinct intron regions of the gene whose expression is targeted for down-regulation. In an exemplary embodiment, a human lung cancer cell line (NCI-H460a) with a homozygous spontaneous K-ras mutation was transfected with a recombinant plasmid that synthesizes a genomic segment of K-ras in antisense orientation. Translation of the mutated K-ras mRNA was specifically inhibited, whereas expression of H-ras and N-ras was unchanged.
    Type: Grant
    Filed: October 13, 1992
    Date of Patent: January 25, 2000
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jack A. Roth, Tapas Mukhopadhyay, Michael A. Tainsky
  • Patent number: 5958892
    Abstract: The present invention details methods for the treatment of cancer. In particular, it concerns the induction of apoptosis of cancer cells following treatment with methoxyestradiol. 2-methoxyestradiol (2-MeOE.sub.2) increase wild-type p53 levels in a human non-small lung cancer cell lines associated with accumulation of cyclin dependent kinase inhibitor p21 WAF1/CIP1. Significant apoptotic cell death occurred after the drug treatment. Thus, 2-MeOE.sub.2 facilitates induction of p53-mediated apoptosis.
    Type: Grant
    Filed: July 30, 1996
    Date of Patent: September 28, 1999
    Assignee: Board of Regents, The University of Texas System
    Inventors: Tapas Mukhopadhyay, Jack A. Roth
  • Patent number: 5747469
    Abstract: The present invention relates to the use of tumor suppressor genes in combination with a DNA damaging agent or factor for use in killing cells, and in particular cancerous cells. A tumor suppressor gene, p53, was delivered via a recombinant adenovirus-mediated gene transfer both in vitro and in vivo, in combination with a chemotherapeutic agent. Treated cells underwent apoptosis with specific DNA fragmentation. Direct injection of the p53-adenovirus construct into tumors subcutaneously, followed by intraperitoneal administration of a DNA damaging agent, cisplatin, induced massive apoptotic destruction of the tumors. The invention also provides for the clinical application of a regimen combining gene replacement using replication-deficient wild-type p53 adenovirus and DNA-damaging drugs for treatment of human cancer.
    Type: Grant
    Filed: April 25, 1994
    Date of Patent: May 5, 1998
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jack A. Roth, Toshiyoshi Fujiwara, Elizabeth A. Grimm, Tapas Mukhopadhyay, Wei-Wei Zhang, Laurie B. Owen-Schaub
  • Patent number: 5691198
    Abstract: A variety of genetic constructs are disclosed that will find both in vitro and in vivo use in the area of tumor biology and cancer therapy. In particular, expression constructs are provided that contain a p16 encoding region and other regulatory elements necessary for the expression of a p16 transcript. One version of the expression construct is a replication-deficient adenoviral vector. Also provided are methods for the transformation of cell lines and the inhibition of cancer cell proliferation.
    Type: Grant
    Filed: July 17, 1995
    Date of Patent: November 25, 1997
    Assignee: Board of Regents, The University of Texas System
    Inventors: Xiaomei Jin, Jack A. Roth
  • Patent number: 5637456
    Abstract: The present invention relates generally to the area of quality control for recombinant agents to be used in gene therapy. Specifically, the invention concerns an assay used to identify the percentage of defective or therapeutically inactive vector in a vector stock.
    Type: Grant
    Filed: February 17, 1995
    Date of Patent: June 10, 1997
    Assignees: The University of Texas, Board of Regents, Rhone Poulenc Rorer
    Inventors: Jack A. Roth, Wei Wei Zhang, Bruno Tocque, Laurent Bracco
  • Patent number: 4704064
    Abstract: An industrial elevator for automatically handling paper rolls at high volume is described. The elevator includes load-receiving platforms at both the initial and final floor levels, interconnected by a chain suspension system such that each platform travels only one-half the distance between floors, meeting at an intermediate level where the roll transfers from one platform to the other before continuing on to the discharge level. Each platform includes a stop arm system which receives a roll, rolling on its lateral edge, absorbing its dynamic energy and bringing the roll to a stop. The roll is cradled on the stop arm such that, on positive release, a rolling motion is imparted to the roll and it rolls from the discharging platform.
    Type: Grant
    Filed: December 30, 1985
    Date of Patent: November 3, 1987
    Assignee: Enterprises International, Inc.
    Inventors: Michael E. Hawley, Jack Roth